We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Santaris Pharma Awarded €1.35M by Denmark’s Advanced Technology Foundation
News

Santaris Pharma Awarded €1.35M by Denmark’s Advanced Technology Foundation

Santaris Pharma Awarded €1.35M by Denmark’s Advanced Technology Foundation
News

Santaris Pharma Awarded €1.35M by Denmark’s Advanced Technology Foundation

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Santaris Pharma Awarded €1.35M by Denmark’s Advanced Technology Foundation"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Santaris Pharma announced that the Danish National Advanced Technology Foundation (ATF) has awarded a grant of €1.35 million towards the development of the first ever drug targeted against a human microRNA.

The drug candidate, SPC3649, is an antagonist of the liver-specific microRNA-122 and is being developed by Santaris in collaboration with the Centre for Biological Sequence Analyses at the Technical University of Denmark and the Department of Cellular and Molecular Medicine, University of Copenhagen.

This is the second award from the Danish ATF to the Santaris Pharma led consortium. In 2006 the ATF made a grant to Santaris and the University of Copenhagen of €1.3m, to support research in the rapidly evolving field of microRNA therapeutics.

Announcing the award, Sakari Kauppinen, Santaris Pharma’s Associate Director of MicroRNA Research, commented, "The entire field of molecular biology and medicine has been thrown wide open in recent years by the discovery of microRNAs. Santaris Pharma’s LNA technology has unique advantages in developing potential breakthrough drugs acting on disease-associated microRNAs."

Kauppinen continued, “We are delighted that the Danish Advanced Technology Foundation has recognised the scientific and commercial potential of our world leading position in this field.  SPC3649 may well become the first microRNA antagonist drug to be tested in human clinical trials.”

Advertisement